Open AccessCharacterization of Differentially Detectable Mycobacterium tuberculosis in the Sputum of Subjects with Drug-Sensitive or Drug-Resistant Tuberculosis before and after Two Months of Therapy
Author(s) -
Kayvan Zainabadi,
Kathleen F. Walsh,
Stalz Charles Vilbrun,
L Mathurin,
Myung Hee Lee,
Kihachi Saito,
Saurabh Mishra,
Oksana Ocheretina,
Jean William Pape,
Carl Nathan,
Daniel W. Fitzgerald
Publication year - 2021
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.00608-21
Subject(s) - pyrazinamide , sputum , ethambutol , tuberculosis , mycobacterium tuberculosis , isoniazid , medicine , drug resistance , microbiology and biotechnology , rifampicin , drug , sputum culture , immunology , pharmacology , biology , pathology
Standard methods for enumeratingMycobacterium tuberculosis in patient sputum can miss large populations of viableM. tuberculosis cells that are unable to grow either on solid medium or in liquid medium unless the medium has been extensively diluted. Because these bacteria can be detected in liquid medium after limiting dilution, they have been termed differentially culturable or differentially detectableM. tuberculosis (DD-Mtb ). Treatment with isoniazid (H), rifampin (R), pyrazinamide (Z), and ethambutol (E) (HRZE) for 1 to 2 weeks has been shown to increase the representation of DD-Mtb in the sputum of drug-sensitive (DS) tuberculosis (TB) patients.